Second Genome Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Employees
  • 13

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 16

Second Genome General Information

Description

Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision therapies and biomarkers. The company's platform uses a microbiome data platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites from the microbiome, enabling researchers to develop medicines through microbiome science.

Contact Information

Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1000 Marina Boulevard
  • Suite 500
  • Brisbane, CA 94005
  • United States
+1 (650) 000-0000

Second Genome Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Second Genome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Sep-2021 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 15-Mar-2019 0000 000.00 00000 Completed Clinical Trials - Phase 2
5. Grant 01-Jan-2019 00.000 000.00 Completed Startup
4. Later Stage VC (Series B) 14-May-2017 000.00 000.00 0000 Completed Startup
3. Early Stage VC (Series A) 07-Jun-2013 00.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 09-Aug-2011 $5M $6.24M 000.00 Completed Startup
1. Seed Round 07-Jul-2010 $1.24M $1.24M 00.00 Completed Startup
To view Second Genome’s complete valuation and funding history, request access »

Second Genome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 5,607,290 $0.000100 $0.02 $0.22 $0.22 1x $0.22 1.45%
To view Second Genome’s complete cap table history, request access »

Second Genome Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision t
Drug Discovery
Brisbane, CA
13 As of 2023
000.00
00000000000 000.00

000000

mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
San Diego, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Emeryville, CA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Second Genome Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Locanabio Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
00000000 000000 Formerly VC-backed Emeryville, CA 000 00000 00000000000 00000
000000000 Formerly VC-backed Vancouver, Canada 000 00000 00000000 00000
00000 (0000 000000 Formerly VC-backed Somerville, MA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Dublin, OH 0 000.00 0000 000.00
You’re viewing 5 of 43 competitors. Get the full list »

Second Genome Patents

Second Genome Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3905893-A1 Microbially derived peptides and proteins for immunotherapy Pending 06-Jan-2019 0000000000
EP-3905893-A4 Microbially derived peptides and proteins for immunotherapy Pending 06-Jan-2019 0000000000
US-20220089653-A1 Microbially derived peptides and proteins for immunotherapy Pending 06-Jan-2019 0000000000
EP-3863655-A1 Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders Pending 09-Oct-2018 0000000000
EP-3863655-A4 Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders Pending 09-Oct-2018 C12N15/746
To view Second Genome’s complete patent history, request access »

Second Genome Executive Team (19)

Name Title Board Seat Contact Info
Todd DeSantis Co-Founder and Vice President of Informatics
Karim Dabbagh Ph.D Chief Executive Officer, Board Member and President
Joseph Porto Ph.D Chief Scientific Officer
Gary Andersen Ph.D Co-Founder and Advisor
Peter Roddy Chief Financial Officer and Advisor
You’re viewing 5 of 19 executive team members. Get the full list »

Second Genome Board Members (14)

Name Representing Role Since
Barbara Dalton Ph.D Pfizer Ventures Board Member 000 0000
Bradley Margus Self Board Member 000 0000
Carole Nuechterlein JD Roche Venture Fund Board Member 000 0000
Corey Goodman Ph.D Self Co-Founder and Chairman 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Second Genome Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Second Genome Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MBL Venture Capital Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Digitalis Ventures Venture Capital Minority 000 0000 000000 0
Justin Kuczynski Angel (individual) Minority 000 0000 000000 0
Lifeforce Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »